ACURX PHARMACEUTICALS, INC.
ACXP US00510M1045
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-45% | -12% | -10% | -80% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Luci David P CEO |
1.02 USD |
49,261 Bought |
50,000 USD |
06/01/2025 | 06/01/2025 |
Deluccia Robert J O |
1.02 USD |
49,261 Bought |
50,000 USD |
06/01/2025 | 06/01/2025 |
Dean Jack H O |
1.02 USD |
9,852 Bought |
10,000 USD |
06/01/2025 | 06/01/2025 |
Scodari Joseph C O |
1.02 USD |
24,631 Bought |
25,000 USD |
06/01/2025 | 06/01/2025 |
Donohue James J. O |
1.02 USD |
9,852 Bought |
10,000 USD |
06/01/2025 | 06/01/2025 |
Sailer Carl O |
1.02 USD |
24,631 Bought |
25,000 USD |
06/01/2025 | 06/01/2025 |